Login to Your Account

2Q Revenue Jumps 38 Percent

Gilead Buying Rest Of Corus; $365M Plus Lawsuit Payout

By Randall Osborne

Friday, July 21, 2006
Just more than three months after pumping $25 million into Corus Pharma Inc., Gilead Sciences Inc. - already Corus' largest shareholder - is exercising its option to buy out the firm, at a price tag of $365 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription